Shares of the Jaguar Health, Inc. (JAGX) stock continued the rising trend in the pre-market trading session today on July 20, 2021. The momentum was created after the announcement of the closing of a financing of Dragon SPAC byDragon SPAC S.p.A. and Napo EU S.p.A, the Italian subsidiary of Napo Pharmaceuticals, which is a wholly-owned subsidiary of JAGX stock. Jaguar stock price saw a push of 8.28% to reach $1.57 a share at the time of this writing. The stock went high by 10.69% at the previous closing. Let’s take a closer look at recent events.
Dragon SPAC Financing:
The gross proceeds for the Dragon SPAC financing were totaled approximately 8,830,000 euros. This financing is the result of previously announced $10.8 million funding by the Jaguar stock into Dragon SPAC. The funds obtained from the recently registered direct offering were used in this financing. The net proceeds resulting from the private placement will be used to finance Dragon SPAC’s merger with Napo EU. Furthermore, the net proceeds would also help in financing the combined activities after the merging of Napo EU and Dragon SPAC. The merger is expected to be completed within the next three months.
How Jaguar Health will help Napo EU:
The Napo EU is dedicated to expanding its plant-based medicines in Europe in order to fulfill the gastrointestinal medical needs of the consumers. The JAGX stock will help Napo EU by providing the exclusive Napo license for the development and commercializing of Crofelemer in the European market.
Completion of Phase 2 HALT-D study:
On July 14, 2021, JAGX stock did announce the completion of the Phase 2 HALT-D study which was initiated by the third-party investigator. The study was related to the evaluation of the effectiveness of Mytesi®, a Crofelemer, against HER2-positive breast cancer patients in order to analyze the symptomatic relief in diarrhea. The Georgetown University sponsored the investigator and Genentech which is a member of Roche Group, did funding.
JAGX annual shareholders’ meeting:
Due to the lack of quorum, the annual shareholders’ meeting of JAGX had been adjourned for the third time and now will be held on August 6, 2021, at the San Francisco office. The record of the eligible JAGX stockholders for the annual meeting is April 12, 2021.
Wrap Up:
So far so good for JAGX stock as far as market sentiment is concerned. Crofelemer’s first-in-class mechanism would prove to be beneficial for the people and would make an impact in the future. Hence JAGX stock can be a good bet for investors in the long run.
